share_log

Maxim Group Upgrades Agile Therapeutics to Buy, Announces $1 Price Target

Maxim Group Upgrades Agile Therapeutics to Buy, Announces $1 Price Target

Maxim Group 将敏捷疗法升级为收购,宣布目标价为1美元
Benzinga Real-time News ·  2022/07/26 08:14

Maxim Group analyst Naz Rahman upgrades Agile Therapeutics (NASDAQ:AGRX) from Hold to Buy and announces $1 price target.

Maxim集团分析师纳兹·拉赫曼将Agile Therapeutics(纳斯达克股票代码:AGRX)从 “持有” 上调至 “买入”,并宣布了1美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发